Diaxonhit SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Diaxonhit SA issues FY 2014 sales guidance and updates on FY 2014 plans
Diaxonhit SA:Sees sales growth in FY 2014.FY 2013 sales 31.2 million euros.FY 2014 sales 32.18 million euros - Thomson Reuters I/B/E/S Estimates.To launch Allomap in FY 2014.To start validation study of Dx15 in FY 2014.
- Share this
- Digg this